Male Breast Cancer Treatment Market Size, Share, Growth Analysis, By Product Type(Chemotherapy, Medication, and Others), By Application(Hospitals, Clinics and Others), By Treatment(Local Treatment, Radiation Therapy, Systemic Treatment and Targeted Therapy), By Region - Industry Forecast 2025-2032

Male Breast Cancer Treatment Market size was valued at USD 20.88 Billion in 2023 and is poised to grow from USD 23.05 Billion in 2024 to USD 50.86 Billion by 2032, growing at a CAGR of 10.4% during the forecast period (2025-2032).

Male breast cancer is an extremely uncommon kind of cancer that develops in a man's breast tissue. It happens when a breast cell divides quickly, resulting in a tumor. Due to the inheritance of aberrant (mutated) genes, particularly the BRCA2 gene, it may run in the family. Though it can happen at any age, it is more common among older men. The ageing population and rising rates of obesity are only two of the many variables that are predicted to propel the market's expansion. As an illustration, the Bristol-Myers Squibb Company and Clovis Oncology announced in July 2017 a wide clinical collaboration for the purpose of assessing the combination of the cancer medications Nivolumab and Rucaparib in Phase 2 and Phase 3 clinical trials across a variety of tumor types.

The American Cancer Society (ACS) estimates that 1 in 833 males will have breast cancer in their lifetime. Less than 1% of all cancers are caused by it. The survival rate has grown because of greater knowledge of male breast cancer, which has led to early cancer diagnosis and prompt, efficient treatment. The factors driving the expansion of the worldwide market for male breast cancer treatments are the rise in cancer cases, the advancement of biotechnology, and the development of novel medicines. But the absence of a comprehensive approach and the expensive price of research and development are impeding this market's expansion.